Correction to: Multi-center, randomized, double-blind, placebocontrolled study of quetiapine extended-release formulation in Japanese patients with bipolar depression

Psychopharmacology (Berl). 2018 Oct;235(10):3079-3080. doi: 10.1007/s00213-018-5013-6.

¹ Institute of CNS Pharmacology, 3-14-20 Sagamiohno, Minami-ku, Sagamihara, Kanagawa, 252-0303, Japan.
² Ohyachi Hospital, Clinical Research Center, 5-7-10 Ohyachi-higashi, Atsubetsu-ku, Sapporo, Hokkaido, 004-0041, Japan.
³ Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
⁴ Department of Clinical Medicine, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.
⁵ Japan/Asia Clinical Development 2, Astellas Pharma Inc., 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan.
⁶ Global Clinical Science, Astellas Pharma Europe B.V, Sylviusweg 62, PO Box 344, 2300 AH, Leiden, The Netherlands.
⁷ Japan-Asia Data Science, Astellas Pharma Inc., 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan.
⁸ Astellas Pharma Global Development, Inc., 1 Astellas Way, Northbrook, IL, 60062, USA.
⁹ Japan/Asia Clinical Development 2, Astellas Pharma Inc., 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan. shinya.kamei@astellas.com.

Abstract

The original version of this article contained a mistake in Table 5. Correct version is presented here.